Paul W. Shabram
Technik-/Wissenschafts-/F&E-Leiter bei BIORA THERAPEUTICS, INC.
Aktive Positionen von Paul W. Shabram
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| BIORA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 25.04.2022 | - |
Karriereverlauf von Paul W. Shabram
Ehemalige bekannte Positionen von Paul W. Shabram
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| EMERGENT BIOSOLUTIONS INC. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
| Ventana Biosciences, Inc. | Gründer | - | - |
Emergent Travel Health, Inc.
 Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01.07.2007 | - |
Ausbildung von Paul W. Shabram
| University of California, Santa Cruz | Undergraduate Degree |
| University of Phoenix | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 7 |
Operativ
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Consumer Services | 3 |
| Technology Services | 2 |
| Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BIORA THERAPEUTICS, INC. | Health Services |
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Emergent Travel Health, Inc.
Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | Technology Services |
| Ventana Biosciences, Inc. |
- Börse
- Insiders
- Paul W. Shabram
- Erfahrung
